Fortitude Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Fortitude Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$292K	Buy	558 +41	+8%	+$21K	0.11%	170
2026 Q2	$257K	Buy	+517	New	+$229K	0.1%	181
2022 Q2	–	Sell	-317	Closed	-$83K	–	1272
2022 Q1	$83K	Hold	317	–	–	0.04%	392
2021 Q4	$70K	Buy	+317	New	+$61.6K	0.04%	446

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Fortitude Advisory Group's VRTX Position: Q3 2026 in Review

Fortitude Advisory Group increased its Vertex Pharmaceuticals (VRTX) stake by 7.9% in Q3 2026, buying an estimated $21K and bringing the position to 558 shares worth $292K. The position accounts for 0.11% of the portfolio, ranked #170.

Fortitude Advisory Group first reported a position in VRTX in Q4 2021 and has held it in 4 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Fortitude Advisory Group held 558 shares of Vertex Pharmaceuticals worth $292K as of Q3 2026.
Fortitude Advisory Group bought 41 Vertex Pharmaceuticals shares in Q3 2026, an estimated $21K.
Vertex Pharmaceuticals made up 0.11% of Fortitude Advisory Group's portfolio in Q3 2026, its #170 holding.
Fortitude Advisory Group first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Fortitude Advisory Group's 13F filing for Q3 2026, filed 15 Oct 2026.